FDA Clears Ravulizumab for Neuromyelitis Optica

Source link : https://www.newshealth.biz/health-news/fda-clears-ravulizumab-for-neuromyelitis-optica/

The US Food and Drug Administration (FDA) has expanded the indication for the long-acting C5 complement inhibitor, ravulizumab (Ultomiris, Alexion), to include adults with anti–aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). Ravulizumab is already approved in the United States to treat adults and children aged 1 or older with paroxysmal nocturnal hemoglobinuria or […]

Author : News Health

Publish date : 2024-03-25 20:13:43

Copyright for syndicated content belongs to the linked Source.